Targeting the transforming growth factor-β signaling pathway in human cancer

Nagaraj Nagathihalli, Pran K. Datta

Research output: Contribution to journalArticle

171 Citations (Scopus)

Abstract

The transforming growth factor-ß (TGF-β) signaling pathway plays a pivotal role in diverse cellular processes. TGF-β switches its role from a tumor suppressor in normal or dysplastic cells to a tumor promoter in advanced cancers. It is widely believed that the Smad-dependent pathway is involved in TGF-β tumor-suppressive functions, whereas activation of Smad-independent pathways, coupled with the loss of tumor-suppressor functions of TGF-β, is important for its pro-oncogenic functions. TGF-β signaling has been considered a useful therapeutic target. The discovery of oncogenic actions of TGF-β has generated a great deal of enthusiasm for developing TGF-β signaling inhibitors for the treatment of cancer. The challenge is to identify the group of patients where targeted tumors are not only refractory to TGF-β-induced tumor suppressor functions but also responsive to the tumor-promoting effects of TGF-β. TGF-β pathway inhibitors, including small and large molecules, have now entered clinical trials. Preclinical studies with these inhibitors have shown promise in a variety of different tumor models. Here, we focus on the mechanisms of signaling and specific targets of the TGF-β pathway that are critical effectors of tumor progression and invasion. This report also examines the therapeutic intervention of TGF-ß signaling in human cancers.

Original languageEnglish (US)
Pages (from-to)77-91
Number of pages15
JournalExpert Opinion on Investigational Drugs
Volume19
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Transforming Growth Factors
Neoplasms
Critical Pathways
Carcinogens
Therapeutics
Clinical Trials

Keywords

  • Cancer therapy
  • Smad signaling
  • Transforming growth factor
  • Tumor invasion
  • Tumor metastasis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Targeting the transforming growth factor-β signaling pathway in human cancer. / Nagathihalli, Nagaraj; Datta, Pran K.

In: Expert Opinion on Investigational Drugs, Vol. 19, No. 1, 01.2010, p. 77-91.

Research output: Contribution to journalArticle

@article{e0e407854adb497d819937022ecc5358,
title = "Targeting the transforming growth factor-β signaling pathway in human cancer",
abstract = "The transforming growth factor-{\ss} (TGF-β) signaling pathway plays a pivotal role in diverse cellular processes. TGF-β switches its role from a tumor suppressor in normal or dysplastic cells to a tumor promoter in advanced cancers. It is widely believed that the Smad-dependent pathway is involved in TGF-β tumor-suppressive functions, whereas activation of Smad-independent pathways, coupled with the loss of tumor-suppressor functions of TGF-β, is important for its pro-oncogenic functions. TGF-β signaling has been considered a useful therapeutic target. The discovery of oncogenic actions of TGF-β has generated a great deal of enthusiasm for developing TGF-β signaling inhibitors for the treatment of cancer. The challenge is to identify the group of patients where targeted tumors are not only refractory to TGF-β-induced tumor suppressor functions but also responsive to the tumor-promoting effects of TGF-β. TGF-β pathway inhibitors, including small and large molecules, have now entered clinical trials. Preclinical studies with these inhibitors have shown promise in a variety of different tumor models. Here, we focus on the mechanisms of signaling and specific targets of the TGF-β pathway that are critical effectors of tumor progression and invasion. This report also examines the therapeutic intervention of TGF-{\ss} signaling in human cancers.",
keywords = "Cancer therapy, Smad signaling, Transforming growth factor, Tumor invasion, Tumor metastasis",
author = "Nagaraj Nagathihalli and Datta, {Pran K.}",
year = "2010",
month = "1",
doi = "10.1517/13543780903382609",
language = "English (US)",
volume = "19",
pages = "77--91",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Targeting the transforming growth factor-β signaling pathway in human cancer

AU - Nagathihalli, Nagaraj

AU - Datta, Pran K.

PY - 2010/1

Y1 - 2010/1

N2 - The transforming growth factor-ß (TGF-β) signaling pathway plays a pivotal role in diverse cellular processes. TGF-β switches its role from a tumor suppressor in normal or dysplastic cells to a tumor promoter in advanced cancers. It is widely believed that the Smad-dependent pathway is involved in TGF-β tumor-suppressive functions, whereas activation of Smad-independent pathways, coupled with the loss of tumor-suppressor functions of TGF-β, is important for its pro-oncogenic functions. TGF-β signaling has been considered a useful therapeutic target. The discovery of oncogenic actions of TGF-β has generated a great deal of enthusiasm for developing TGF-β signaling inhibitors for the treatment of cancer. The challenge is to identify the group of patients where targeted tumors are not only refractory to TGF-β-induced tumor suppressor functions but also responsive to the tumor-promoting effects of TGF-β. TGF-β pathway inhibitors, including small and large molecules, have now entered clinical trials. Preclinical studies with these inhibitors have shown promise in a variety of different tumor models. Here, we focus on the mechanisms of signaling and specific targets of the TGF-β pathway that are critical effectors of tumor progression and invasion. This report also examines the therapeutic intervention of TGF-ß signaling in human cancers.

AB - The transforming growth factor-ß (TGF-β) signaling pathway plays a pivotal role in diverse cellular processes. TGF-β switches its role from a tumor suppressor in normal or dysplastic cells to a tumor promoter in advanced cancers. It is widely believed that the Smad-dependent pathway is involved in TGF-β tumor-suppressive functions, whereas activation of Smad-independent pathways, coupled with the loss of tumor-suppressor functions of TGF-β, is important for its pro-oncogenic functions. TGF-β signaling has been considered a useful therapeutic target. The discovery of oncogenic actions of TGF-β has generated a great deal of enthusiasm for developing TGF-β signaling inhibitors for the treatment of cancer. The challenge is to identify the group of patients where targeted tumors are not only refractory to TGF-β-induced tumor suppressor functions but also responsive to the tumor-promoting effects of TGF-β. TGF-β pathway inhibitors, including small and large molecules, have now entered clinical trials. Preclinical studies with these inhibitors have shown promise in a variety of different tumor models. Here, we focus on the mechanisms of signaling and specific targets of the TGF-β pathway that are critical effectors of tumor progression and invasion. This report also examines the therapeutic intervention of TGF-ß signaling in human cancers.

KW - Cancer therapy

KW - Smad signaling

KW - Transforming growth factor

KW - Tumor invasion

KW - Tumor metastasis

UR - http://www.scopus.com/inward/record.url?scp=72049091524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049091524&partnerID=8YFLogxK

U2 - 10.1517/13543780903382609

DO - 10.1517/13543780903382609

M3 - Article

C2 - 20001556

AN - SCOPUS:72049091524

VL - 19

SP - 77

EP - 91

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 1

ER -